Cargando…
Radiopharmaceuticals for Relapsed or Refractory Leukemias
Radiopharmaceuticals, meaning drugs that hold a radionuclide intended for use in cancer patients for treatment of their disease or for palliation of their disease-related symptoms, have gained new interest for clinical development in adult patients with relapsed or refractory leukemia. About one-thi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397856/ https://www.ncbi.nlm.nih.gov/pubmed/30859091 http://dx.doi.org/10.3389/fonc.2019.00097 |
_version_ | 1783399474166497280 |
---|---|
author | Kunos, Charles A. Capala, Jacek Ivy, Susan Percy |
author_facet | Kunos, Charles A. Capala, Jacek Ivy, Susan Percy |
author_sort | Kunos, Charles A. |
collection | PubMed |
description | Radiopharmaceuticals, meaning drugs that hold a radionuclide intended for use in cancer patients for treatment of their disease or for palliation of their disease-related symptoms, have gained new interest for clinical development in adult patients with relapsed or refractory leukemia. About one-third of adult patients outlive their leukemia, with the remainder unable to attain complete remission status following the first phase of treatment due to refractory bone marrow or blood residual microscopic disease. The National Cancer Institute (NCI) Cancer Therapy Evaluation Program conducted 49 phase 1-1b trials in adult patients with leukemia between 1986 and 2017 in an effort to discover tolerated and effective therapeutic drug combinations intended to improve remission and mortality rates. None of these trials involved radiopharmaceuticals. In this article, the NCI perspective on the challenges encountered in and on the future potential of radiopharmaceuticals alone or in combination for adult patients with relapsed or refractory leukemia is discussed. An effort is underway already to build-up the NCI's clinical trial enterprise infrastructure for radiopharmaceutical clinical development. |
format | Online Article Text |
id | pubmed-6397856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63978562019-03-11 Radiopharmaceuticals for Relapsed or Refractory Leukemias Kunos, Charles A. Capala, Jacek Ivy, Susan Percy Front Oncol Oncology Radiopharmaceuticals, meaning drugs that hold a radionuclide intended for use in cancer patients for treatment of their disease or for palliation of their disease-related symptoms, have gained new interest for clinical development in adult patients with relapsed or refractory leukemia. About one-third of adult patients outlive their leukemia, with the remainder unable to attain complete remission status following the first phase of treatment due to refractory bone marrow or blood residual microscopic disease. The National Cancer Institute (NCI) Cancer Therapy Evaluation Program conducted 49 phase 1-1b trials in adult patients with leukemia between 1986 and 2017 in an effort to discover tolerated and effective therapeutic drug combinations intended to improve remission and mortality rates. None of these trials involved radiopharmaceuticals. In this article, the NCI perspective on the challenges encountered in and on the future potential of radiopharmaceuticals alone or in combination for adult patients with relapsed or refractory leukemia is discussed. An effort is underway already to build-up the NCI's clinical trial enterprise infrastructure for radiopharmaceutical clinical development. Frontiers Media S.A. 2019-02-25 /pmc/articles/PMC6397856/ /pubmed/30859091 http://dx.doi.org/10.3389/fonc.2019.00097 Text en Copyright © 2019 Kunos, Capala and Ivy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kunos, Charles A. Capala, Jacek Ivy, Susan Percy Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title | Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title_full | Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title_fullStr | Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title_full_unstemmed | Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title_short | Radiopharmaceuticals for Relapsed or Refractory Leukemias |
title_sort | radiopharmaceuticals for relapsed or refractory leukemias |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397856/ https://www.ncbi.nlm.nih.gov/pubmed/30859091 http://dx.doi.org/10.3389/fonc.2019.00097 |
work_keys_str_mv | AT kunoscharlesa radiopharmaceuticalsforrelapsedorrefractoryleukemias AT capalajacek radiopharmaceuticalsforrelapsedorrefractoryleukemias AT ivysusanpercy radiopharmaceuticalsforrelapsedorrefractoryleukemias |